Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

Various Technological Advancements are set to Grow the Global Biotechnology Market

PR Newswire November 9, 2018

IntelGenx Reports Third Quarter 2018 Financial Results

GlobeNewswire November 8, 2018

IntelGenx Announces Definitive Agreement with Tilray® to Form an Exclusive, Worldwide Partnership for Cannabis-Infused VersaFilm™ Products

GlobeNewswire November 7, 2018

IntelGenx to Report Third Quarter 2018 Financial Results on November 8, 2018 – Conference Call to Follow

GlobeNewswire November 1, 2018

The Spanish Agency of Medicines and Medical Devices Grants Marketing Authorization of RIZAPORT®

GlobeNewswire October 31, 2018

IntelGenx Announces Exercise of Over-Allotment Option

GlobeNewswire October 26, 2018

IntelGenx Completes US$12 Million Equity Offering

GlobeNewswire October 22, 2018

IIROC Trading Resumption - IGX; IGX.DB

Canada NewsWire October 18, 2018

IntelGenx Announces Pricing of $12 Million Equity Offering

GlobeNewswire October 18, 2018

IIROC Trading Halt - IGX, IGX.DB

Canada NewsWire October 17, 2018

IntelGenx Announces Proposed Equity Offering

GlobeNewswire October 17, 2018

IntelGenx Receives Over $1.6 Million from Exercise of Warrants

GlobeNewswire October 17, 2018

IntelGenx Partner Insud Pharma Submits ANDA for Co-Developed Generic Buccal Film Product

GlobeNewswire October 4, 2018

Patient Recruitment to Commence in IntelGenx’s Phase 2a Montelukast VersaFilm™ Trial in Mild to Moderate Alzheimer’s Disease

GlobeNewswire September 25, 2018

IntelGenx Announces Successful Results from RIZAPORT® Bioequivalence Study

GlobeNewswire September 24, 2018

IntelGenx Signs Letter of Intent with Tilray® to Enter Into a World-Wide Agreement To Produce Cannabis-Infused VersaFilm™ Products

GlobeNewswire September 20, 2018

IntelGenx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire August 30, 2018

IntelGenx Reports Second Quarter 2018 Financial Results

GlobeNewswire August 9, 2018

IntelGenx to Report Second Quarter 2018 Financial Results on Aug 9, 2018 – Conference Call to Follow

GlobeNewswire August 2, 2018

IntelGenx Receives CIPO Notice of Allowance for Loxapine VersaFilm™ Patent

GlobeNewswire July 5, 2018